Comprehensive rehabilitation in chronic heart failure
More details
Hide details
Physical Culture Centre, Maria Curie-Skłodowska University, Lublin, Poland
Department of Zoonoses, Institute of Rural Health, Lublin, Poland
Ann Agric Environ Med 2013;20(3):606–612
Chronic heart failure (CHF) is a complex disease process connected with cardiovascular system as well as other organs and skeletal muscles. In connection with the above, cardiac rehabilitation, consisting of exercise training and diet supplementation, aims at recovery of physical, social and psychic function and removing risk factors influencing the occurrence of circulatory system diseases. Evidence has shown that exercise training in CHF patients, both aerobic and resistance, can increase peak oxygen consumption and exercise capacity, improve NYHA (New York Heart Association) functional class, reduce mortality and improve the quality of life. Evidence suggests that most improvement is due to the effects of training on the peripheral circulation and skeletal muscle, rather than on the heart itself. Exercise training can improve skeletal muscle metabolism, increase blood flow within the active skeletal muscles, increase capillary density, promote the synthesis and release of nitric oxide, improve angiogenesis, and decrease oxidative stress. Physical effort reduces sympathetic arousal and increases parasympathetic arousal, thus reducing cardiac dysrythmia and ischemia. Mitochondria start working harder, as the demand for energy is higher and electron flow provides energy in the form of ATP. Studies have consistently demonstrated that exercise training is safe and has no deleterious effect on central haemodynamics, left ventricular remodeling, systolic or diastolic function, or myocardial metabolism. Taking several supplements that have documented roles in medical therapy, including vitamins B, C and E, coenzyme Q10, alpha-lipoic acid, chromium, omega-3 polyunsaturated fatty acids, L-carnitine, and quercetin, has beneficiary effect on many diseases, including CHF. In our experience, 19 patients with CHF who undertook resistance (weight) training and food supplementation, returned to their normal activities after 4 months, without any complaints.
Adam Gąsiorowski   
Physical Culture Centre, Maria Curie-Skłodowska University, Lublin, Poland
1. Zatoński WA, and the HEM project team. Epidemiological analysis of health situation development in Europe and its causes until 1990. Ann Agric Environ Med. 2011; 18: 194–202.
2. Zatoński WA, Mańczuk M, and Kielce PONS team. POlish-Norwegian Study (PONS): research on chronic non-communicable diseases in European high risk countries – study design. Ann Agric Environ Med. 2011; 18: 203–206.
3. Islami F, Mańczuk M, Vedanthan R, Vatten L, Polewczyk A, Fuster V, Boffetta P, Zatoński WA. A cross-sectional study of cardiovasculardisease and associated factors. Ann Agric Environ Med. 2011; 18: 255–259.
4. Szuba A, Martynowicz H, Zatońska K, Ilow R, Regulska-Ilow B, Różańska D, Wołyniec M, Einhorn J, Vatten L, Asvold BO. Prevalence of hypertension in a sample of Polish population – baseline assessment from the prospective cohort ‘Pons’ study. Ann Agric Environ Med. 2011; 18: 260–254.
5. Yusuf S. Case of the PONS study. Ann Agric Environ Med. 2011; 18: 279–280.
6. Boyle P. Improving health in Central and Eastern Europe. Ann Agric Environ Med. 2011; 18: 281- 282.
7. Wojtyła A. Closing the health gap. Ann Agric Environ Med. 2012; 19: 1–2.
8. Wise FM. Exercise based cardiac rehabilitation in chronic heart failure. Austr Fam Physician. 2007; 36: 1019–1024.
9. Cahalin LP. Heart failure. Phys Ther. 1996; 76: 516–533.
10. Dalal HM, Wingham J, Palmer J, Taylor R, Petre C, Lewin R. Why do so few patients with heart failure participate in cardiac rehabilitation? A cross-sectional survey from England, Wales and Northern Ireland. BMJ Open 2012; 2: e000787.
11. Jeon YH, Kraus SG, Jowsey T, Glasgow NJ. The experience of living with chronic heart failure: a narrative review of qualitative studies. BMC Health Serv Res. 2010; 10: 77.
12. Piña IL, Apstein CS, Balady GJ, Belardinelli R, Chaitman BR, Duscha BD, Fletcher BJ, Fleg JL, Myers JN, Sullivan MJ. Exercise and heart failure: A statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention. Circulation. 2003; 107: 1210–1225.
13. Greenleaf J. Some evils of prolonged bed-rest deconditioning. Med. Sportiva. 2001; 5(4): 205–228.
14. Mitkowski P. Heart failure – epidemy of 21st century. Cardiovascular Diseases 2004; 1: 43–50.
15. Wujek-Krajewska E, Kaczorowska M, Kuch M. Heart failure – epidemy of 21st century – challenge for cardiac rehabilitation. Kardioprofil. 2007; 5: 201–207.
16. Papathanasiou G, Tsamis N, Georgiadou P, Adamopoulos S. Beneficial effects of physical training and methodology of exercise prescription in patients with heart failure. Hellenic J Cardiol. 2008; 49: 267–277.
17. Coats AJ, Adamopoulos S, Meyer TE, et al. Effects of physical training in chronic heart failure. Lancet 1990; 335: 63–66.
18. Arnold JMO, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Can J Cardiol. 2006; 22: 23–45.
19. Clark AL. Exercise and heart failure: assessment and treatment. Heart 2006; 92: 699–703.
20. Dubach P, Sixt S, Myers J. Exercise training in chronic heart failure: why, when and how. Swiss Med Wkly. 2001; 131: 510–514.
21. European Heart Failure Training Group. Experience from controlled trials of physical training in chronic heart failure: protocol and patient factors in effectiveness in the improvement in exercise tolerance. Eur Heart J. 1998; 19: 466–475.
22. Gibbs CR, Jackson G, Lip GYH. ABC of heart failure. Non drug management. BMJ. 2000; 320: 366–369.
23. Ko JK, McKelvie RS. The role of exercise training for patients with heart failure. Eura Medicophys. 2005; 41:35–47.
24. Knocke A. Program description: physical therapy in a heart failure clinic. Cardiopulm Phys Ther J. 2012; 23: 46–47.
25. Uren NG, Lipkin DP. Exercise training as therapy for chronic heart failure. Br Heart J. 1992; 67: 430–433.
26. Lloyd-Williams F, Mair FS, Leitner M. Exercise training and heart failure: a systematic review of current evidence. Br J Gen Pract. 2002; 52:47–55.
27. Dafoe W, Huston P. Current trends in cardiac rehabilitation Can Med Assoc J. 1997; 156: 527–532.
28. Fiatarone MA, O’Neil EF, Doyle N, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Appl Physical. 1988; 64: 1038–1044.
29. Frontera WR, Meredith CN, O’Reilly KP, et al. Strength conditioning in aldermen skeletal muscle hypertrophy and improved function. J Appl Physiol. 1988; 64: 1038–1044.
30. Kostka T. The role of physical activity in promoting health among the elderly. Med Sportiva 2001; 5 (suppl. 2): 147–150.
31. Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation. 1999; 99: 1173–1182.
32. Tavazzi L, Giannuzzi P. Physical training as a therapeutic measure in chronic heart failure: time for recommendations. Heart 2001; 86: 7–11.
33. Coats AJ. What causes the symptoms of heart failure. Heart 2001; 86: 574–578.
34. Rees K, Taylor RS, Singh S, Coats AJ, Ebrahim S. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev. 2004; (3): CD003331.
35. Amundsen BH, Wisløff U, Slørdahl SA. Exercise training in cardiovascular diseases. Tidsskr Nor Laegeforen. 2007; 127: 446–448 (in Norwegian).
36. Deskur-Śmielecka E, Jóźwiak A, Dylewicz P. Cardiac rehabilitation in the elderly. Kardiol Pol. 2008; 66: 684–687.
37. Hwang CL, Chien CL, Wu YT. Resistance training increases 6-minute walk distance in people with chronic heart failure: a systematic review. J Physiother. 2010; 56: 87–96.
38. Coats AJ. Exercise training for heart failure. Coming of age. Circulation. 1999; 99: 1138–1140.
39. Blumenthal JA. New frontiers in cardiovascular behavioral medicine: Comparative effectiveness of exercise and medication in treating depression. Cleveland Clin J Med. 2011; 78 (Suppl. 1): S35-S43.
40. Giannuzzi P, Temporelli PL, Corra U et al. ELVO-CHF Study Group V: antiremodeling effect of long-term in patients with stable chronic heart failure results of the exercise in left ventricular dysfunction and chronic heart failure (ELVD-CHF) trial. Circulation. 2003; 108: 554–559.
41. Klecha A, Kawecka, Jaszcz K, Bacior B et al. Physical training in patients with chronic heart failure of ischemic origin: effect on exercise capacity and left ventricular remodelling. Eur J Cardiovasc Prev Rehabil. 2007; 14: 85–91.
42. Mc Kelvie RS, Teo KK, Roberts R, McCartney N, Humen D, Montague T et al. Effects of exercise training for patients with heart failure: The Exercise Rehabilitation Trial (EXERT). Am Heart J. 2002; 144: 23–30.
43. Davies EJ, Moxham T, Rees K, Singh S, Coats AJ, Ebrahim S, Lough F, Taylor RS. Exercise based rehabilitation for heart failure. Cochrane Database Syst Rev. 2010; (4): CD003331.
44. Davies EJ, Moxham T, Rees K, Singh S, Coats AJS, Ebrahim S, Lough F, Taylor RS. Exercise training for systolic heart failure: Cochrane systematic review and meta-analysis. Eur J Heart Failure 2010; 12: 706–715.
45. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2001; CD001800.
46. Dalal HM, Zawada A, Jolly K, Moxham T, Taylor RS. Home based versus centre based cardiac rehabilitation: Cochrane systematic review and meta-analysis. BMJ. 2010; 340: b5631. doi: 10.1136/bmj.b5631.
47. Węgrzynowska-Teodorczyk K, Jankowska EA, Banasiak W, Ponikowski P, Woźniewski M. Significance of resistance training for the attenuation of skeletal myopathy in chronic heart failure. Kardiol Pol. 2008; 66: 434–442.
48. Papas AM. The Vitamin E factor. Muza SA, Warsaw 2001.
49. Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002; 82: 47–95.
50. Bove PF, van der Vlat A. Nitric oxide and reactive nitrogen species in airway epithelial signalling and inflammation. Free Radic Biol Med. 2006; 40: 368–406.
51. Smart N, Marvick TH. Exercise training for patients with heart failure: a systemic review of factors that improve mortality and morbidity. Am J Med. 2004; 116: 693–706.
52. Piepoli MF, Davos C, Francis DP, Coats AJ; Extra MATCH Collaboration. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004; 328: 189.
53. Dekkers JC, Van Doornen LJ, Kemper HC. Sports Medicine 1996.
54. Pauling L. How to live longer and feel better. WH Freeman and Company, New York 1986.
55. Sesso HD, Paffenbarger RSJr, Lee JM. Physical activity and coronary heart disease in men: The Harvard Alumni Health Study. Circulation. 2000; 102(9): 975–980.
56. Sheps DS, et al. The INTERHEART study: intersection between behavioral and general medicine. Psychosom Med. 2004; 66(6): 797–808.
57. Safi F, et al. Leisure time but not occupational physical activity significantly affects cardiovascular risk factors in an adult population. Eur J Clin Invest. 2007; 37(12): 947–953.
58. Warburton DE, Nicol CW, Bredin SS. Prescribing exercise as preventive therapy. CMAJ. 2006; 174(7): 961–974.
59. Schmidt S, Schuchert A, Krieg T, Oeff M. Home telemonitoring in patients with Chronic Heart Failure. A Chance to Improve Patient Care? Dtsch Arztebl Int. 2010; 156: 527–532.
60. Piotrowicz E. How to do: Telerehabilitation in heart failure patients. Cardiology J. 2012; 19: 243–248.
61. von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res. 2007; 73: 298–309.
62. Rath M. Reducing the risk for cardiovascular disease with nutritional supplements. J Orthomolec Med. 1992, 3: 1–6.
63. Janson M. Orthomolecular medicine: the therapeutic use of dietary supplements for anti-aging. Clin Interv Aging. 2006; 1(3): 261–265.
64. Alsafwah S, Laguardia SP, Arroyo M, Dockery BK, Bhattacharya SK, Ahokas RA, Newman KP. Congestive heart failure is a systemic illness: a role for minerals and micronutrients. Clin Med Res. 2007; 5: 238–243.
65. Rath M, Pauling L. Solution to the puzzle of human cardiovascular disease: Its primary cause is ascorbate deficiency, leading to the deposition of Lipoprotein (a) and fibrinogen (fibrin) in the vascular wall. J Orthomolec Med. 1991; 6: 125–134.
66. Armstrong VW, Cremer P, Eberle E et al. The association between serum lipoprotein(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL-levels. Atherosclerosis 1986; 62: 249–257.
67. Beisiegel V, Niendorf A, Wolf K, Reblin T, Rath M. Lipoprotein(a) in the arterial wall. Europ Heart J. 1990; 11: 174–183.
68. Lavie CJ. Marked benefit with sustained-release niacin (Vit B3) therapy in patients with isolated very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol. 1992; 69: 1085–1093.
69. Sies H, Stahl W. Vitamins E and C carotene and other carotenoids as antioxidants. Am J Clin Nutr. 1995; 62: 1315–1321.
70. Riemersma RA, Wood DA, Maciutyre CCA, Elton RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamin A, C and E and carotene. Lancet. 1991; 337: 1–5.
71. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996; 347: 781–786.
72. Gąsiorowski A, Dutkiewicz J. Weight training and appropriate nutrient supplementation as an alternative method to pharmacological treatment in rehabilitation of post-myocardial infarction patients. Ann Agric Environ Med. 2012; 19: 333–338.
73. Genest JJr, Jenner JL, Mc Namara JR, Ordovas JM, Silberman SR, Wilson PWF, Schaefer EJ. Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. Am J Cardiol. 1991; 67: 1039–1045.
74. Ginter E. Vitamin C deficiency, cholesterol metabolism, and atherosclerosis. J Orthomolec Med. 1991; 6: 166–173.
75. Herman WJ, Ward K, Fancett J. The effect of tocopherol on high-density lipoprotein cholesterol. Am J Clin Pathol. 1979; 72: 848–852.
76. Azen S, Qian D, Mack WJ et al. Effect of supplementary antioxidant vitamin intake on carotin arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation. 1996, 94(10): 2369–2372.
77. Langsjoem PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. Pronounced increase of survival of patients with cardiomyopathy when treated with coenzyme Q10 and conventional therapy. Int J Tissue React. 1990; 13 (3): 163–168.
78. Ghidini O, Azzurro M, Vita A, Sartori G. Evaluation of the therapeutic efficacy of L-Carnitine in congestive heart failure. Int J Clin Pharmacol Therapy Toxicol. 1988; 26: 217–220.
79. Folkers K, Langsioem P, Willis R, Richardson P, Xial J, Ye CQ, Tamagawa H. Lovastatin decreases coenzyme Q10 levels in humans. Proc Natl Acad Sci. 1990; 87: 8931–8934.
80. Digiesi V. Mechanism of action of coenzyme Q10 in essential hypertension. Curr Therap Res. 1992; 51: 668–672.
81. Folkers K, Yammamura Y. Biomedical and clinical aspects of coenzyme Q10. Elsevier Science Publishers, New York 1986.
82. Kamikawa T, Kobayashi A, Emaciate T, Hayashi H, Yamazaki N. Effect of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol. 1985; 56: 247–251.
83. Shimon J, Almog S, Vered Z, et al. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med. 1995; 98: 485–490.
84. Sies H, Stahl W. Vitamins E and C- carotene and other carotenoids as antioxidants. Am J Clin Nutr. 1995; 62: 1315–1321.
85. Duda MK, O’Shea KM, Stanley WC. Omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res. 2009; 84: 33–41.
86. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology. 1992; 3: 194–202.
87. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation. 1996; 94: 6–9.
88. Ginter E. Vitamin C deficiency, cholesterol metabolism, and atherosclerosis. J Orthomolec Med. 1991; 6: 166–183.
89. Traber MG. Heart disease and single-vitamin supplementation. Am J Clin Nutr. 2007; 85: 293S-299S.
90. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA 2005; 294: 56–65.
91. Robinson K, Arheart K, Refsum H, et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation. 1998, 97(5): 437–443.
92. Rath M, Pauling L. A unified theory of human cardiovascular disease leading the way to the abolition of this disease as a cause for human mortality. J Orthomolec Med. 1992; 7: 5–15.